Simplex Trading’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-2,100
Closed -$1K 10198
2023
Q4
$1K Sell
2,100
-500
-19% -$301 ﹤0.01% 8633
2023
Q3
$1K Buy
2,600
+500
+24% +$613 ﹤0.01% 8469
2023
Q2
$6K Buy
+2,100
New +$6.35K ﹤0.01% 7863
2022
Q4
Sell
-780
Closed -$16K 10744
2022
Q3
$16K Buy
780
+560
+255% +$15.1K ﹤0.01% 7795
2022
Q2
$5K Sell
220
-293
-57% -$9.97K ﹤0.01% 8888
2022
Q1
$25K Sell
513
-577
-53% -$28.5K ﹤0.01% 8007
2021
Q4
$76K Sell
1,090
-1,053
-49% -$88.7K ﹤0.01% 6668
2021
Q3
$220K Buy
2,143
+23
+1% +$2.19K ﹤0.01% 5447
2021
Q2
$213K Buy
2,120
+2,098
+9,536% +$204K ﹤0.01% 5580
2021
Q1
$206K Sell
22
-20
-48% -$2.03K ﹤0.01% 4699
2020
Q4
$348K Sell
42
-7
-14% -$597 ﹤0.01% 3895
2020
Q3
$420K Buy
49
+25
+104% +$2.91K ﹤0.01% 3208
2020
Q2
$226K Buy
+24
New +$1.32K ﹤0.01% 3860
2018
Q4
Hold
0
-$2K 7991
2018
Q3
Hold
0
7114
2018
Q2
Hold
0
7067

Simplex Trading's VBIV Position: Q3 2024 in Review

Simplex Trading sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 19,351 shares — an estimated $12K sold.

Simplex Trading first reported a position in VBIV in Q2 2018 and held it in 18 quarters. The position peaked at $212K in Q3 2020. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

  • Simplex Trading reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
  • Simplex Trading sold 19,351 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $12K.
  • Simplex Trading first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2018 and held it in 18 quarters.
  • Simplex Trading's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $212K in Q3 2020.
  • 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Simplex Trading's 13F filing for Q3 2024, filed 8 Nov 2024.